ADRB3 and neoplasm: Therefore, to confirm that SR59230A administration brought its effects blocking mainly the β3-AR subtype, we first investigated and confirmed the β3-AR protein expression on lymphocytes of TDLNs and on tumor-infiltrating T cells.